CMAST: New partnership launched to facilitate the development of new drugs for children across Europe


conect4children (c4c) is a large collaborative paediatric network that will facilitate the development of new drugs and other therapies for children in Europe. In support of Janssen, CMAST – a leading consultancy and project management company in life sciences - is involved in this six-year project. The kick-off meeting, taking place from May 23rd to May 25th at Bayer AG in Berlin (Germany), brings together key stakeholders across academia and industry.

c4c aims to set up an infrastructure that optimises the delivery of clinical trials in children across Europe through:

  • a single point of contact for all sponsors, sites and investigators;
  • efficient implementation of trials - adopting consistent approaches, aligned quality standards and coordination of sites at national and international level;
  • collaboration with specialist and national networks;
  • high quality input to study design and preparation through rigorous strategic and operational feasibility assessment;
  • the promotion of innovative trial design and quantitative science methods;
  • an education and training platform to shape the future leaders of paediatric drug development;
  • the development of sustainable support for all these activities.

The consortium is a collaboration between academic and private sectors including 33 academic and 10 industry partners from 20 European countries, more than 50 third parties and around 500 affiliated partners.

With a budget of about €140m (IMI2 support of €67m and industry partners’ in-kind contribution of €73m), c4c is one of the biggest initiatives funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement n º 777389. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest Public Private Partnership and is funded jointly by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

The project is coordinated and led by Fondazione PENTA, The University of Liverpool, Janssen Pharmaceutica NV and Bayer AG.
More info about this project can be found on

Disclaimer - This communication reflects the views of the c4c Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein


CMAST is a leading consultancy and project management company in life sciences.
With a team of more than 90 industry experts, CMAST provides support to pharma and life sciences companies, universities and research institutes.
The company offers consultancy, project management and tangible business solutions in the following areas:

  • Early stage innovation services
  • Funding services
  • Project & Portfolio Management
  • R&D process optimization
  • Multi-stakeholder collaborations
  • Regulatory compliance & quality
  • Health data analytics & visualization
  • Supply chain

CMAST is headquartered in Temse (Belgium) and has branches in Switzerland, Germany, Poland and the US. Since 2018 CMAST is part of Modis Life Sciences, a subdivision of The Adecco Group, which gives the company a global reach. More info on



Interested in a regular update of the Life Sciences and biotech sector in Flanders?